Elsevier

The Lancet

Volume 339, Issue 8804, 23 May 1992, Pages 1279-1281
The Lancet

CLINICAL PRACTICE
Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

https://doi.org/10.1016/0140-6736(92)91601-4Get rights and content

Abstract

Sulphasalazine extends remissions and lessens disease activity during relapses of ulcerative colitis, but it also causes many adverse side-effects. The adverse reactions are mostly attributable to the sulphapyridine carrier moiety rather than the active principle 5-aminosalicylic acid (5-ASA), so agents to deliver 5-ASA to the colon by other means have been designed. We have compared the efficacy and tolerability of two such agents, olsalazine and mesalazine, in maintenance therapy of ulcerative colitis. 100 patients with ulcerative colitis in remission were recruited at one centre and assigned randomly to treatment with olsalazine (Dipentum; 1·0 g daily) or mesalazine (Asacol, with Eudragit-S coating; 1·2 g daily). Compliance, biochemical and haematological variables, and clinical evidence of disease activity were assessed every 3 months for 12 months by observers unaware of treatment allocation. In intention-to-treat analysis, which included as treatment failures patients withdrawn for protocol violations, adverse reactions, intercurrent illness, or non-compliance as well as those with relapses of ulcerative colitis, the olsalazine group had a significantly lower rate of treatment failure than the mesalazine group (12/49 [24%] vs 23/50 [46%]; p=0·025). Analysis restricted to 64 patients still in remission at 1 year and 18 with relapses also showed a significant difference in relapse rate (olsalazine 5/42 [12%] vs mesalazine 13/40 [33%]; p = 0·024). Both drugs were well tolerated; only 9 patients reported substantial side-effects. Olsalazine was clearly superior to mesalazine in prevention of relapses in ulcerative colitis, especially in patients with left-sided disease.

References (28)

  • Km Das et al.

    Adverse reactions during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype

    N Engl J Med

    (1973)
  • MA. Peppercorn

    Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development

    Ann Intern Med

    (1984)
  • G. Jrnerot

    Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease

    Drugs

    (1989)
  • Cited by (0)

    View full text